Affimed Reports Results for Cancer Therapy in NSCLC Patients
Affimed Reports Results for Cancer Therapy in NSCLC Patients
Affimed N.V. (NASDAQ:AFMD) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.
致力于让患者恢复与生俱来的抗癌能力的临床阶段免疫肿瘤学公司Affimed N.V.（纳斯达克股票代码：AFMD）（“Affimed” 或 “公司”）今天公布了正在进行的针对严重预处理的非小细胞肺癌患者进行AFM24/阿替唑单抗联合疗法的 AFM24-102 试验的最新临床数据。研究结果继续表明，在非小细胞肺癌eGfRWT和EgfrMut患者中有意义的临床活性，耐受性良好。此外，该公司报告了对接受 480 mg AFM24 治疗的患者进行的事后暴露反应分析的结果，结果显示，较高的 AFM24 暴露量与明显更好的反应率、PFS 的改善和总存活率 (OS) 的改善有关。根据这些数据，AFM24 的未来开发计划每周将使用 720 mg 的剂量，该剂量已在 AFM24 的 1 期研究中成功测试，显示出可控的安全性。
